Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
794 ARTICLES BY Jacob Bell
- Jan. 18, 2019 Lilly suspends Lartruvo promotion after Phase 3 failure
- Jan. 17, 2019 Boehringer building out biologics manufacturing in China
- Jan. 17, 2019 Lilly rushed its Loxo deal to have a big reveal at JPM
- Jan. 16, 2019 Aptinyx stung by pain drug's mid-stage miss
- Jan. 11, 2019 At JPM, the NASH flood gates start to crack
- Jan. 11, 2019 The winners and losers from JPM 2019
- Jan. 11, 2019 J&J raises prices as Dems introduce bills aimed at lowering drug costs
- Jan. 10, 2019 Spark looks at scale, manufacturing as gene therapy matures
- Jan. 10, 2019 A biotech's M&A invitation and Editas' next CRISPR step
- Jan. 9, 2019 FDA warns it won't be long before user fee funding runs dry
- Jan. 8, 2019 Pain, depression and antipsychotic drugs drum up enthusiasm
- Jan. 8, 2019 Sage soars on success of postpartum depression drug
- Jan. 7, 2019 Pharmas spending too much on buybacks, not enough on big deals: report
- Jan. 4, 2019 How Bristol-Myers' big buy could spur ripples for pharma M&A
- Jan. 3, 2019 Seeking edge in oncology, Bristol-Myers bets big on blood cancer, cell therapies
- Dec. 19, 2018 Eyeing NASH, Gilead wagers $1.5B on preclinical fibrosis drugs
- Dec. 18, 2018 Vertex chalks up another win for pain drug
- Dec. 17, 2018 Clovis dips as Tesaro reveals more details of its acquisition
- Dec. 14, 2018 Merck shelling out $3.7B on digital solutions for animal health
- Dec. 13, 2018 Biogen backs away from AGTC after gene therapy failure
- Dec. 12, 2018 Lilly bets on AC Immune's tech to target Alzheimer's
- Dec. 11, 2018 Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment
- Dec. 6, 2018 Conatus unsuccessful in spinning NASH failure
- Dec. 5, 2018 3 questions leaving ASH
- Dec. 5, 2018 Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'